Based in Tokyo, Japan, CMIC HOLDINGS Co., Ltd. serves as a leading provider of extensive services to the pharmaceutical industry within Japan. Its operational framework is structured across five strategic segments: Contract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO), Contract Sales Organization (CSO), Healthcare, and Innovative Pharma Model. Through its CRO capabilities, the company orchestrates comprehensive clinical trial services, encompassing everything from clinical operations, precise data management, and medical writing to patient recruitment, pharmacovigilance, project leadership, and stringent audit and quality assurance, alongside expert statistical analysis. Additionally, it offers critical consulting expertise in areas like clinical site network development, drug formulation, health economics, market entry strategies, and regulatory navigation, including advice on national health insurance pricing for medical devices and in vitro diagnostics. CMIC's CDMO division is instrumental in drug development and manufacturing, handling commercial supply, contract development, investigational product manufacturing, and specialized tasks such as packaging, labeling, release and stability testing, and technology transfer, bolstered by advanced formulation, process, and analytical development services. The company also operates sophisticated laboratory facilities, delivering bioanalysis, GLP/GMP analysis, and studies on biomarkers, large and small molecules, oligonucleotides, and conducting thorough toxicity, safety pharmacology, and non-clinical assessments. Within its Healthcare segment, CMIC focuses on patient and healthcare support, offering innovative solutions like drug adherence programs, specialized health platforms (harmo, Helc+), extensive prescription drug databases, and personalized health checks (selcheck). Beyond these, its portfolio includes post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing support, and efficient clinical research coordinating and site management services. Demonstrating its commitment to innovation, CMIC HOLDINGS Co., Ltd. has entered into a strategic partnership with Science 37, Inc. to advance the adoption of decentralized clinical trials, thereby accelerating the progress of new treatment development. The company was originally established in 1985.